However, the mechanisms by which DR5 operates and its potential clinical applications in liver fibrosis are still largely unexplored; future studies should aim to detail the specific regulatory mechanisms of TRAIL-DR5 in liver fibrosis and the differential expression between fibrotic and healthy liver cells to improve the safety and effectiveness of DR5-targeted therapies. The gene discussed is TNFRSF10B; the disease is Hepatic fibrosis.